v3.26.1
Organization and Business Description (Tables)
 6 Months Ended
Mar. 31, 2026
Organization and Business Description [Line Items]  
Schedule of Consolidated Financial Statements of the Company

The unaudited condensed consolidated financial statements of the Company include the following entities:

 

Name of Entity   Date of
Incorporation		   Place of
Incorporation		   % of
Ownership		     Principal Activities
Jin Med   January 14, 2020   Cayman Islands     Parent      Investment holding
                     
Zhongjin HK   February 25, 2020   Hong Kong     100%     Investment holding
                     
Erhua Med   September 24, 2020   PRC     100%     WFOE, Investment holding
                     
Changzhou Zhongjin   January 26, 2006   PRC     VIE      Design, development, manufacturing and sales of wheelchair and other mobility products
                     
Taizhou Zhongjin   June 17, 2013   PRC     100% controlled subsidiary of the VIE      Design, development, manufacturing and sales of wheelchair and other mobility products
                     
Zhongjin Jing’ao   December 18, 2014   PRC     100% controlled subsidiary of the VIE      Design, development, manufacturing and sales of wheelchair and other mobility products
                     
Zhongjin Kangma   August 21, 2023   PRC     80% controlled subsidiary of the VIE     Sales of wheelchair and other mobility products
                     
Anhui Zhongjin   October 7, 2023   PRC     100%     Not in operation yet
                     
Zhongjin Kangma Health   February 19, 2025   PRC     100% controlled subsidiary of the Zhongjin Kangma     Newly incorporated – not in operation yet
                     
Guangxi Zhongjin   December 11, 2025   PRC     100%     Newly incorporated – not in operation yet
VIE [Member]  
Organization and Business Description [Line Items]  
Schedule of Financial Statement Amounts and Balances of the VIE and VIE’s Subsidiaries

The following financial statement amounts and balances of the VIE and VIE’s subsidiaries were included in the accompanying unaudited condensed consolidated financial statements after elimination of intercompany transactions and balances:

 

   March 31,
2026		   September 30,
2025		 
Current assets  $38,033,969   $38,865,435 
Non-current assets   1,639,611    1,622,787 
Total assets  $39,673,580   $40,488,222 
Current liabilities  $21,887,820   $23,438,856 
Non-current liabilities   
-
    
-
 
Total liabilities  $21,887,820   $23,438,856 
Schedule of Revenue
   For the Six Months Ended
March 31,		 
   2026   2025 
Net revenue  $8,919,382   $9,881,505 
Net (loss) income  $(197,950)  $207,608 
Schedule of Cash Flow Statement
   For the Six Months Ended
March 31,		 
   2026   2025 
Net cash (used in) provided by operating activities  $(516,587)  $2,919,587 
Net cash provided by (used in) investing activities  $2,400,625   $(4,297,134)
Net cash (used in) provided by financing activities  $(1,444,594)  $4,901,089